Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis?
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
24478
Cancer Research UK - United Kingdom
C33043/A24478
Cancer Research UK - United Kingdom
PubMed
31813449
DOI
10.1016/j.trecan.2019.10.011
PII: S2405-8033(19)30204-3
Knihovny.cz E-zdroje
- Klíčová slova
- cancer therapy, invasiveness, metastasis, migrastatic treatment,
- MeSH
- invazivní růst nádoru genetika MeSH
- lidé MeSH
- metastázy nádorů MeSH
- nádorové buněčné linie MeSH
- nádory komplikace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The concept of 'migrastatics' allows the development of a new drug class that is neither cytotoxic nor antiproliferative but is solely directed towards inhibition of cancer cell motility. Given that the regulatory pathway is open, and migrastatic candidates have been described, it is the right time to enter a new era of antimetastatic treatment.
Citace poskytuje Crossref.org
Migrastatic therapy as a potential game-changer in adaptive cancer treatment
Synthesis and migrastatic activity of cytochalasin analogues lacking a macrocyclic moiety
The emerging role of microtubules in invasion plasticity
Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Are We Ready for Migrastatics?
Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model
Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19
